Serum's Bilthoven acquisition opens door to cut-price polio vaccine in Europe and US
This article was originally published in Scrip
Executive Summary
Serum Institute's acquisition of the government-owned Dutch manufacturer of monoclonal antibodies and vaccines, Bilthoven Biologicals, is expected to change the market dynamics for injectable polio vaccines, the capability and technology for which is currently vested in just three global facilities. The buyout will also provide the Indian firm with a manufacturing foothold in the West, boosting its plans to expand into Europe and the US.
